Odyssey Therapeutics Director Jeffrey M. Leiden purchased $100,000 worth of stock at $20.00 per share, marking the largest insider purchase in the company's history. This significant buy signals confidence in the company's valuation and strategic direction following recent market volatility.
Price context
The stock is currently trading at $17.23, down 14.62% from its 52-week high of $20.18, but remains 10.66% above its 52-week low of $15.57.
Catalysts to watch
- •Q2 2026 earnings on June 30, 2026, which showed a net loss of US$52.79 million and a loss per share of US$1.74.
- •Upcoming collaboration with Evotec announced on August 7, 2026, to leverage AI-enabled R&D capabilities.
- •The largest insider purchase in company history occurred on May 8, 2026, indicating strong insider conviction.
Risks
- •The company reported a net loss of US$52.79 million in Q2 2026, significantly higher than the US$41.24 million loss a year earlier.
- •The stock is trading at a forward P/E of -4.76, reflecting high expectations for future profitability.
AI-generated context from public data. Not investment advice. Verify before trading.